TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04022889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTERCEPT Treated Platelets
Description: Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) and stored for 7days at 20-24°C with continuous agitation. Samples from the Test component will be processed with either the BEST or the Variant 1 procedure prior to radiolabeling. The radiolabeled autologous Test and Control platelets (approximately 10-30 mL) will be simultaneously administered intravenously into the subject.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTERCEPT Treated Platelets
Description: Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) and stored for 7days at 20-24°C with continuous agitation. Samples from the Test component will be processed with either the BEST or the Variant 1 procedure prior to radiolabeling. The radiolabeled autologous Test and Control platelets (approximately 10-30 mL) will be simultaneously administered intravenously into the subject.
Study: NCT01912222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXAZOMIB
Study: NCT02621502

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anhydrous Glucose
Description: On the intervention day, the volunteers will consume the control product.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire.
Study: NCT03694119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenelzine
Description: Phenelzine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tyramine
Description: Tyramine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tyramine
Description: Tyramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyramine
Description: Tyramine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenelzine placebo
Description: Phenelzine placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenelzine placebo
Description: Phenelzine placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenelzine placebo
Description: Phenelzine placebo
Study: NCT01912222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXAZOMIB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXAZOMIB
Study: NCT03298607

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 months treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Serelys PMS
Description: 2 months treatment
Study: NCT01727492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidantia
Study: NCT03285295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay
Description: For all donor specimens with investigational Alinity s HBsAg and Alinity s HBsAg Confirmatory results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alinity s HTLV I/II Assay
Description: For all donor specimens with investigational Alinity s HTLV I/II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alinity s Anti-HCV Assay
Description: For all donor specimens with investigational Alinity s Anti-HCV results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alinity s HIV Ag/Ab Combo Assay
Description: For all donor specimens with investigational Alinity s HIV Ag/Ab Combo results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alinity s Anti-HBc Assay
Description: For all donor specimens with investigational Alinity s Anti-HBc results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alinity s Chagas Assay
Description: For all donor specimens with investigational Alinity s Chagas results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
Study: NCT05245604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJO-087
Description: Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine ophthalmic solution 0.05%
Description: Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day
Study: NCT03015116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Daily foot and ankle stretching protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Daily foot and ankle stretching protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Daily foot and ankle stretching protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Daily cryotherapy in conjunction with stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Daily cryotherapy in conjunction with stretching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Daily cryotherapy in conjunction with stretching

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Low Power
Description: Photobiomodulation treatment with 10W power output

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation High Power
Description: Photobiomodulation treatment with 25W power output
Study: NCT02011256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable loop-recorder
Description: All patients not diagnosed with atrial fibrillation with regular ECG or 72-hour Holter-monitoring will receive an ILR for 3 years.
Study: NCT04057911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active NIBS
Description: Cathodal noninvasive brain stimulation will be given for 20 mins.
Study: NCT06648044

Intervention type: OTHER
Group type: OTHER
Intervention: Description: Research of therapeutic targets in the frame of nephronophthisis and renal associated ciliopathie

Intervention type: OTHER
Group type: OTHER
Intervention: Description: Research of therapeutic targets in the frame of nephronophthisis and renal associated ciliopathie

Intervention type: OTHER
Group type: OTHER
Intervention: Description: Research of therapeutic targets in the frame of nephronophthisis and renal associated ciliopathie

Intervention type: OTHER
Group type: OTHER
Intervention: Description: Research of therapeutic targets in the frame of nephronophthisis and renal associated ciliopathie
Study: NCT04283292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Topical Capsaicin for the treatment of Cannabinoid Hyperemesis Syndrome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo cream that is applied once topically
Study: NCT04664946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of neuroprotective agents
Description: Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.
Study: NCT01292421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B antigen peptide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B antigen peptide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B antigen peptide
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally (PO)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally (PO)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally (PO)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunoenzyme technique
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study: NCT03694119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ozanimod placebo
Description: ozanimod placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ozanimod placebo
Description: ozanimod placebo
Study: NCT03593421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synthetic PreImplantation Factor
Description: peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synthetic PreImplantation Factor
Description: peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synthetic PreImplantation Factor
Description: peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synthetic PreImplantation Factor
Description: peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synthetic PreImplantation Factor
Description: peptide
Study: NCT04504266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWER
Description: This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
Study: NCT01918150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titan 2 stents
Description: The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cobalt-Chromium Bare Metal Stents
Description: The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
Study: NCT00497770

Intervention type: DRUG
Intervention: Pemetrexed
Description: Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient

Intervention type: DRUG
Intervention: Pemetrexed
Description: Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient

Intervention type: DRUG
Intervention: Pemetrexed
Description: Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient

Intervention type: DRUG
Intervention: Pemetrexed
Description: Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient
Study: NCT04805697

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: subjects drank 50 ml , 1 bottle a day for 8 week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fermented grape drinks
Description: subjects drank 50 ml , 1 bottle a day for 8 week
Study: NCT03129191

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive bone conduction hearing aid A
Description: The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an elastic headband.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive bone conduction hearing aid A
Description: The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an elastic headband.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive bone conduction hearing aid B
Description: The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive bone conduction hearing aid B
Description: The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.
Study: NCT03613558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is an alpha-2 agonist that provides both sedation and analgesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline solution
Study: NCT01649648

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cord blood
Description: Baby's own umbilical cord blood
Study: NCT02189018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Exercise
Description: Active exercise on a treadmill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Neuromuscular electrical stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss and active exercise
Description: Weight loss and active exercise on a treadmill

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ad lib activity at home
Description: Ad lib activity at home
Study: NCT03694119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozanimod
Description: ozanimod
Study: NCT04546516

Intervention type: DEVICE
Intervention: HYAcorp Lips and HYAcorp Face
Description: Dermal filler injection to different facial areas
Study: NCT02599090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle.
Study: NCT01735968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST571 + BYL719
Description: Evaluable patients must meet the minimum treatment and safety evaluation requirements of the study. Patients will be treated until they experience progression of disease, withdraw consent, or experience unacceptable toxicity. One study cycle equals 28 days.
Study: NCT02266290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: taping of ankle sprain
Description: All participants were taped for a lateral ankle sprain. The individual is in supine position keeping the foot and ankle in a neutral position. The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: taping of ankle sprain
Description: All participants were taped for a lateral ankle sprain. The individual is in supine position keeping the foot and ankle in a neutral position. The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sport tex® kinesiotape

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pretape Cramer®
Study: NCT00317200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle
Study: NCT03794661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinician programmer electrode screening mode tool
Description: Provides a standardized workflow to guide clinicians or trained healthcare providers through the deep brain stimulation monopolar review screening process
Study: NCT01573767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 100mcg
Description: all subjects recieve open-label Flovent twice daily duirng the run in and treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 100mcg
Description: all subjects recieve open-label Flovent twice daily duirng the run in and treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 100mcg
Description: all subjects recieve open-label Flovent twice daily duirng the run in and treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate 100mcg
Description: all subjects recieve open-label Flovent twice daily duirng the run in and treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation powder during treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vilanterol
Description: subjects will recieve 4 weeks via NDPI during treament period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vilanterol
Description: subjects will recieve 4 weeks via NDPI during treament period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vilanterol
Description: subjects will recieve 4 weeks via NDPI during treament period
Study: NCT02004899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
Study: NCT03175692

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Exome Sequencing
Description: Using next generation sequencing to analysis patient's whole exome. To explore the pathogenic gene variation.
Study: NCT00527644

Intervention type: DEVICE
Group type: OTHER
Intervention: 5mm spring clip
Description: Microline Pentax 5mm Visu-Loc Clip Applier
Study: NCT02939027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Brachytherapy (6,1 Gy)
Description: A total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days/week, during 3 weeks or lees, at least 2 days apart each fraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Brachytherapy (7 Gy)
Description: A total a dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days/week during 3 weeks or lees, at least 2 days apart each fraction.
Study: NCT04175782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS) protocol
Description: Preoperative:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative:~Use of short-acting anesthetic agents Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Refraining from the use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results
Study: NCT02599597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-assisted iCBT
Description: 13 week long individualized prevention program containing, physical activation, sleep management, tailored cognitive behavioral therapy for individual problems.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monthly screening with feedback
Description: Participants are screened with a depression inventory each month and receives feedback from a therapist on the results

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly screening with feedback
Description: Participants are screened with a depression inventory each month and receives feedback from a therapist on the results